Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Featured Stories

Dealing With Brexit: EMA Offers Firms Advice On More Thorny Questions

The European Medicines Agency has updated its guidance on Brexit to offer companies more advice on the regulatory changes they will need to make in areas like transfers of MAs, rapporteurships and orphan designations, multi-country packs, and Article 58 opinions.

Brexit United Kingdom Approvals

CAR-T Reimbursement Threatened By Medicare Coverage Analysis, Manufacturers Say

Novartis, Gilead/Kite and Celgene protest the US Centers for Medicare and Medicaid Services’ decision to launch a Medicare coverage analysis for CAR-T drugs because it might lead to coverage restrictions.

Medicare ImmunoOncology Pricing Strategies

Industry May Like FDA's Biosimilar Guidance Withdrawal, But Not The New Information Vacuum

Sponsors may have to rely even more on the advice they receive from formal meetings as FDA decides to rewrite draft guidance on statistical approaches to evaluate analytical similarity for biosimilars.

Biosimilars FDA Regulation

Venezuela Shuns ‘Multinational Pharmaceutical Cartel’ And Turns To Pan American Health Organization

Venezuela has accused the pharmaceutical industry of holding up medicines supplies and says it will acquire them instead through the Pan American Health Organization.

South America Venezuela Emerging Markets

US FDA Performance Tracker

European Performance Tracker

Global Pharma Guidance Tracker – May 2018

Stay up to date on regulatory guidelines from around the world, with the Pink Sheet's Guidance Tracker.
International Europe Australia

Clinical and Research Excellence Awards 2018 eBook

The Clinical and Research Excellence (CARE) Awards provides an opportunity for the pharma industry to celebrate all its achievements, and pay tribute to the people and teams behind these feats. 2017 was a successful year for the industry, which was evident by the volume and quality of the entries received for this year’s CARE Awards.

Read the eBook and discover more

Generics In The US 2018

Read this eBook and learn more about the West AccelTRA elastomer components program that was designed to help in this effort. Learn how the AccelTRA component program has been helping generic biopharmaceutical manufacturers by providing a number of key features, for those high-volume products and where manufacturers would like to deal mostly with one high-performing elastomer component.

Read the eBook and discover more

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

US FDA May Prioritize Pediatric Cancer Studies By Level Of 'Substantial Relevance'

Assessing the extent of a molecular target's substantial relevance to pediatric cancer could give sponsors more regulatory certainty as to whether they likely would be required to conduct pediatric investigations early in a drug’s development, US FDA's Gregory Reaman says at advisory committee review of molecular target candidate lists.

Advisory Committees Pediatrics Clinical Trials

Latest From Regulation

Keeping Track: Bristol Tests US FDA’s TMB Tolerance, Celltrion Resubmits Herceptin Biosimilar, Nocdurna Approved At Last

The latest drug development news and highlights from our US FDA Performance Tracker.

United States Drug Review

CBER Implements Pre-Clinical Meeting Program For Biologics, Gene Therapy Sponsors

INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.

Biologics Research and Development Strategies

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Advisory Committees Drug Review

Latest From Policy

With 5-0 Winning Streak, Bayer And J&J Move To Eliminate Remaining Xarelto Litigation

Firms want Fifth Circuit to review whether federal law preempts failure-to-warn and design-defect claims; ruling in their favor could end 20,000-plus pending US cases.

Legal Issues Policy

Ireland Clarifies Requirements For Generic Interchangeability

Ireland has amended its guideline on generics interchangeability to clarify that a demonstration of bioequivalence is not a requirement for inclusion on the list of interchangeable medicines.
Generic Drugs Ireland

Does AbbVie Have 'Unclean Hands' From Building Humira Patent Thicket? Judge Allows Discovery

Magistrate judge says Boehringer's theory 'may or may not be viable' as an infringement defense; permits third party subpoenas for information on clinical trials.

Biosimilars Intellectual Property

Clinical / R&D Explore this Topic

Set Alert for Clinical R&D

Latest From Research & Development

BARDA Official Worries About How Non-Traditional Antibiotics Will Get To Market

Promising non-traditional antibiotic therapies need a clear path to market to entice investment, US Biomedical Advanced Research and Development Authority official says.

Infectious Diseases Clinical Trials

Roche’s External Control Arms Show What Real-World Evidence Can Look Like In Practice

With Flatiron, Roche is at the forefront of the emerging field of RWE. Roche Pharma President O’Day described how the company is using such data in the real world of regulation and reimbursement.

Clinical Trials Digital Health

Kite’s CAR-T Therapy Makes It Back Onto EMA’s PRIME, Along With Three New Products

The four latest products to be accepted onto the European Medicines Agency’s popular priority medicines scheme target mantle cell lymphoma, chikungunya, hematopoietic stem cell transplant patients, and the rare monogenic disease, X-linked myotubular myopathy.

Regulation Market Access

Commercial Explore this Topic

Set Alert for Commercial

Latest From Commercial

AbbVie's Elagolix May Be Cost Effective, But Will Test Health Budgets – ICER

Third-party value assessment organization says AbbVie/Neurocrine's elagolix would be cost effective for endometriosis and associated pain, using a placeholder price of $7,000 per year. But the cost would be substantial for health budgets given the broad prevalence of the condition. 

Gynecology & Urology Cost Effectiveness

Biosimilar Substitution: US State Laws Require Physician Communication And, In Some Cases, Lower Prices

Bills allowing pharmacies to substitute biosimilars for reference biologics have been enacted in all but six states. Interactive map notes state-by-state provisions.

Biosimilars State News

Branded Advair Breathes Another Day; Mylan Says A CRL Is On The Way For A Generic

FDA alerted Mylan to expect a complete response letter related to its ANDA for generic Advair. The company said it still could receive an approval prior to the standard 90-day time period after responding to the letter, because the application has a priority designation.

Generic Drugs Respiratory

Manufacturing Explore this Topic

Set Alert for Manufacturing

Latest From Manufacturing

PIC/S Adopts New Guide On Cross-Contamination, Transposes EU GMP Requirements

The group representing international pharmaceutical inspectorates, PIC/S, has issued new guidance on controlling cross-contamination in shared facilities. It has also transposed several EU guidelines on good manufacturing practice that non-EEA participating authorities can adopt on a voluntary basis. 
International Europe

FDA Lauds St. Gallen's Findings On 10 Metrics For Ensuring Drug Quality

US FDA touts new evidence that high performance of pharmaceutical manufacturing sites on 10 quality maturity metrics correlates with robust pharmaceutical quality systems, operational excellence and good business. An FDA-funded study by St. Gallen also finds that low performance, on the other hand, correlates with manufacturing problems.

United States Manufacturing

ANDA Amendments Cannot Get Mid-Review Communications Like Full Applications - FDA

Generic industry officials ask that information requests and discipline review letters be issued during ANDA amendment assessments, but the US agency says they are not allowed in GDUFA II.

FDA Generic Drugs

Consumer / OTC Drugs Explore this Topic

Set Alert for Consumer OTC Drugs

Latest From Consumer

Oral Contraceptive OTC Proposal Moves Closer With Start Of Actual Use Study

HRA Pharma started recruiting in April for an actual use trial, using oral contraceptives with norgestrel 0.075 mg, and expects to complete its study in April 2019, according to's database. Advocacy group Ibis Reproductive Health, which is working with HRA on an NDA for an OTC oral contraceptive, called the start of the study a "pivotal moment" in moving birth control drugs out of Rx-only.

Consumer Prescription To Otc Switch

AMA Encourages Oral Contraceptive OTC Options In Policy Update

AMA members agree to strengthen association's policy language supporting approval and reimbursement of OTC contraceptives.
Consumer Prescription To Otc Switch

For Kamedis, Botanicals Plus OTC Topical Equals Acne Remedy Claim

"We can say we are OTC but the botanicals are doing a lot of the heavy lifting," says Kelli Rodriquez, the firm's sales and marketing chief. Salicylic acid supports the acne treatment claim under an OTC monograph; leaving out benzoyl peroxide, an allergen for some consumers, also allows labeled use more frequently with a claim of faster symptom reduction.

Consumer Dermatology